BEIJING and HANGZHOU, China, Oct. 7, 2024 /PRNewswire/ -- The 32nd United European Gastroenterology...
HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a c...
* A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and resul...
HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., ...
* Oral ecnoglutide was safe and well tolerated with gastrointestinal side effects as the most com...
* Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c...
HANGZHOU, China and SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a c...
* Results from three clinical studies show ecnoglutide to be safe and well-tolerated, and demonst...
HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a c...
- Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 ...
HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a c...
The partnership combines Sciwind's expertise in disease biology and clinical development capabiliti...
* Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14...
- Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose - Up to 88% of participants ...
HANGZHOU, China and SAN FRANCISCO, June 9, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a cl...
HANGZHOU, China and SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a ...
HANGZHOU, China and SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a c...
HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a cl...
HANGZHOU, China and SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a c...
HANGZHOU, China and SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a c...